Haynes Boone represented PATHOMIQ, Inc., a pioneer in artificial intelligence-driven diagnostics, in securing an exclusive U.S. licensing agreement with Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine. The new collaboration will bring PATHOMIQ_PRAD, a cutting-edge AI technology platform for prostate cancer, to patients, and it will empower clinicians with more precise diagnostic insights and personalized treatment plans.
While PATHOMIQ will supply the AI-enabled tests, Myriad will oversee commercialization, bringing the technology to a broader patient population to inform critical treatment decisions throughout the patient journey, from initial biopsy to post-surgical care. Myriad plans to launch its first AI-driven prostate cancer clinical test using this technology later in 2025.
Haynes Boone Partners Phil Albert and Roger Royse provided counsel for PATHOMIQ throughout the deal process, including regulatory considerations and licensing strategy.
“Our collaboration with Myriad, a leader in cancer diagnostic tests, will help to advance precision medicine and improve prostate cancer disease outcomes,” Rajat Roy, CEO and co-founder of PATHOMIQ, said in a statement.
PATHOMIQ_PRAD leverages AI to analyze digital images from biopsy or surgical specimens, predicting patient outcomes, treatment response and genotype mutations quickly and at lower cost. This image-based technology delivers results in just one to two days, providing clinicians with timely, actionable information.
Haynes Boone’s Emerging Companies and Venture Capital Practice Group partners with entrepreneurs, startups and investors, offering guidance on entity formation, financings, commercial agreements, mergers, acquisitions and exits across industries such as technology, healthcare and fintech.
